Shares of Neurocrine Biosciences Inc. (NBIX) were down in Monday's premarket session. The reason? The company just announced it's opening its wallet to the tune of $2.9 billion to buy Soleno Therapeutics Inc. (SLNO).

The deal is for $53.00 per share in cash. Neurocrine plans to pay for it using cash on hand and some pre-payable debt. As of the end of last year, the company reported having about $2.54 billion in cash, cash equivalents, and marketable securities sitting around, so it has a solid foundation to start from.

The Big Prize: Vykat XR

So, what's Neurocrine getting for its money? The crown jewel is a drug called Vykat XR. This isn't just any drug; it's the first treatment approved by the FDA for hyperphagia—that's the uncontrollable hunger—in people with Prader-Willi syndrome (PWS), a rare genetic disorder.

For Neurocrine, this is a strategic play to bulk up its portfolio in endocrinology and rare diseases, markets known for their high growth potential. The company believes adding Vykat XR could be a major driver for its revenue down the line. They're expecting to wrap up the acquisition within the next 90 days.

And it's not just potential; Vykat XR is already pulling in real money. In 2025, it generated $190 million in revenue, with $92 million of that coming in just the fourth quarter. That's a pretty strong start for a drug that only got the FDA's green light in March of 2025.

Of course, not everyone has been a fan. Back in August 2025, a firm called Scorpion Capital put out a short report criticizing Vykat XR, calling it overpriced and raising safety concerns for children with PWS. It's a reminder that even promising drugs come with their share of controversy.

What the Charts Say About Neurocrine

Let's talk about Neurocrine's stock for a second. At a recent price of $131.00, it's trading about 4.5% below its 200-day simple moving average. For the chart-watchers out there, that often signals a bearish trend over the longer term. There's also a lack of clear short-term momentum, which traders might want to keep an eye on.

But it's not all gloomy. Look back over the past year, and the stock has delivered a 12-month return of 41.13%. That's not too shabby and shows there's been solid investor interest. The stock is currently sitting between its 52-week high of $160.18 and low of $84.23, which suggests there might be room to run if things go well.

For those playing the levels, analysts are watching $135.00 as a key resistance point—a ceiling the stock needs to break through. On the flip side, $122.50 is seen as important support; a drop below that could mean more selling pressure.

A Growth-Heavy Profile

Looking at Neurocrine through a multi-factor lens reveals a company heavily tilted toward growth. A market data analysis gives it a high growth score of 88.39, suggesting strong potential. Its quality score, which often reflects the balance sheet, is a decent 62.19. The value score is more moderate at 59.44, hinting the stock might be trading at a bit of a premium compared to its peers. Momentum is fairly neutral at 52.61.

The verdict here is that Neurocrine's story is primarily a growth one, backed by what looks like a solid financial foundation.

ETF Exposure and The Market's Verdict

For investors who prefer to get their exposure through ETFs, Neurocrine pops up in a few places. It has a 5.02% weight in the Tema Neuroscience and Mental Health ETF (MNTL), a 2.59% weight in the SPDR S&P Biotech ETF (XBI), and a smaller 0.48% weight in the iShares Morningstar Small-Cap Growth ETF (ISCG).

As for the immediate market reaction, it was a classic "buyer gets sold, seller gets bought" scenario. Neurocrine Biosciences shares were down 2.74% at $128.00 in premarket trading. Meanwhile, Soleno Therapeutics shareholders are celebrating, with shares up a hefty 32.84% at $52.46.